Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from ImExHS Limited ( (AU:IME) ).
IMEXHS Limited reported a Q2 FY25 revenue of $6.6 million, a slight decrease compared to the previous corresponding period, but an increase when excluding one-off sales. The company has announced a capital raising of $2.6 million to support growth and has expanded its partner program significantly, contributing to 40.6% of software revenue. Operationally, IMEXHS secured a major contract with Neurológico de México and continued the rollout of its AQUILA+ platform. Despite facing challenges in the Colombian healthcare market due to political reforms, the company has implemented strategies to manage working capital and improve profitability through cost reductions and technological advancements.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.75 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
More about ImExHS Limited
IMEXHS Limited is an innovative provider of cloud-based medical imaging software and radiology services, operating across 18 countries.
Average Trading Volume: 30,870
Technical Sentiment Signal: Sell
Current Market Cap: A$15.02M
Learn more about IME stock on TipRanks’ Stock Analysis page.